Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK
● The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker...
top of page
News
Jul 12
Charlotte Casebourne Stock moves on from Theolytics to next entrepreneurial endeavour
Oxford, UK, 12 July 2024 Today Theolytics, a clinical stage biotechnology company harnessing viruses to combat disease, announced that...
Apr 17
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science...
Mar 21
Mike Grey appointed Executive Chair of Theolytics’ Board of Directors
Mike brings decades of operational and board experience gained in Pharma, Biotech and Venture Capital to Theolytics Oxford, UK, March...
Nov 28, 2023
Theolytics presents data at ESMO on its lead program being developed for Ovarian Cancer
Theolytics presents data at ESMO on its lead program being developed for Ovarian Cancer
ahead of first in human clinical trials anticipated
Jun 9, 2023
Theolytics presents data on THEO-260 and THEO-310 at ASCO and EHA
Oxford, UK, 9 June 2023 - Theolytics, a biotechnology company harnessing viruses to combat disease, today announces data presentations at...
Oct 6, 2022
Theolytics presents CAF-targeting therapy for stromal rich tumours, and strengthens leadership team
Oxford, UK, 6th October 2022 - Theolytics, a biotechnology company harnessing viruses to combat disease, will release data on their...
May 31, 2022
Theolytics' £1M project with InnovateUK to develop a novel therapy for multiple myeloma patients
Theolytics kick-starts a £1M project in collaboration with The University of Sheffield, supported by Innovate UK, to develop a novel...
Jul 8, 2021
Theolytics expands Series A financing and welcomes M Ventures as a new investor
Theolytics is harnessing viruses to combat cancer: transforming patients’ lives; through world leading science; with a great team....
Jul 1, 2021
Theolytics is taking part in the BIA Research Relay 2021
We’re delighted to announce that we’re all taking part in the BioIndustry Association’s Research Relay 2021 to raise money for Ovarian...
Nov 6, 2020
Theolytics awarded Innovate UK boost to help combat ovarian cancer
Theolytics has been awarded a grant by Innovate UK, the UK’s innovation agency, to optimise their oncolytic virus candidate for treatment...
Sep 21, 2020
Theolytics announces appointment of Immatics’ Carsten Reinhardt to its Board of Directors
Theolytics, today announced the Board appointment of Carsten Reinhardt MD PhD. Oxford, UK, 21st September 2020 Theolytics, a biotech...
Jan 7, 2020
Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures
Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies. Oxford,...
bottom of page